81-81-2PJVWKTKQMONHTI-UHFFFAOYNA-NPJVWKTKQMONHTI-UHFFFAOYSA-N
WarfarinCoumadin
2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-
(.+-.)-Warfarin
(.+-.)-Warfarin-alcohol
(RS)-Warfarin
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin
3-(α-Acetonylbenzyl)-4-hydroxycoumarin
3-(α-Phenyl-β-acetylethyl)-4-hydroxycoumarin
3-(α-Phenyl-β-acetylethyl)-4-hydroxy-coumarin
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
Athrombine-K
BENZOPYRAN(2H-1)-2-ONE, 4-HYDROXY-3-(3-OXO-1- PHENYLBUTYL)-
Brumolin
Coumafen
Coumafene
Coumaphen
Coumarin, 3-(α-acetonylbenzyl)-4-hydroxy-
Coumefene
Dethmor
DL-3-(α-Acetonylbenzyl)-4-hydroxycoumarin
Kumader
Kumatox
NSC 59813
rac-Warfarin
Ratron G
Rodafarin
Rodafarin C
Temus W
Vampirinip II
Vampirinip III
W.A.R.F. 42
WARF compound 42
warfarina
Warfarine
Zoocoumarin
DTXSID502374281-82-3DEKWZWCFHUABHE-UHFFFAOYNA-NDEKWZWCFHUABHE-UHFFFAOYSA-N
CoumachlorDTXSID80417975836-29-3ULSLJYXHZDTLQK-UHFFFAOYNA-NULSLJYXHZDTLQK-UHFFFAOYSA-N
CoumatetralylDTXSID80417993691-35-8UDHXJZHVNHGCEC-UHFFFAOYNA-NUDHXJZHVNHGCEC-UHFFFAOYSA-N
Chlorophacinone1H-Indene-1,3(2H)-dione, 2-[(4-chlorophenyl)phenylacetyl]-
1,3-Indandione, 2-[(p-chlorophenyl)phenylacetyl]-
1H-Indene-1,3(2H)-dione, 2-[2-(4-chlorophenyl)-2-phenylacetyl]-
2-[(4-Chlorophenyl)phenylacetyl]-1H-indene-1,3-(2H)-dione
2-[(p-Chlorophenyl)phenylacetyl]-1,3-indandione
2-[2-Phenyl-2-(4-chlorophenyl)acetyl]-1,3-indandione
2-Acetyl-2-(p-chlorophenyl)-2-phenylindan-1,3-dione
2-Phenyl-p-chlorophenylacetyl-1,3-indandione
Chlorodiphacinone
Chlorophacinon
Chlorphacinone
Chlorphenacone
clorofacinona
Liphadione
Raticide
Raticide-Caid
Redentin
DTXSID203234882-66-6JYGLAHSAISAEAL-UHFFFAOYSA-NJYGLAHSAISAEAL-UHFFFAOYSA-N
DiphacinoneDTXSID403237883-26-1RZKYEQDPDZUERB-UHFFFAOYSA-NRZKYEQDPDZUERB-UHFFFAOYSA-N
Pindone1H-Indene-1,3(2H)-dione, 2-(2,2-dimethyl-1-oxopropyl)-
2-Pivalyl-1,3-indandione
Pival
DTXSID1025930PR:000007299prothrombinPR:P70375coagulation factor VII (mouse)PR:P16294coagulation factor IX (mouse)PR:O88947coagulation factor X (mouse)CHEBI:33284nutrientD001779blood coagulation factorsCHEBI:28384vitamin KPR:000004191androgen receptorD064417Vitamin K Epoxide ReductasesUBERON:0000062organCHEBI:15422ATPUBERON:0002049vasculaturePR:000030444osteocalcinPR:P19788matrix Gla protein (mouse)GO:0007599hemostasisMP:0001914hemorrhageGO:0042060wound healingMI:1139carboxylation reactionGO:0006810transportGO:1990748cellular detoxificationMP:0001577anemiaGO:0042373vitamin K metabolic processGO:0023052signalingGO:0003824catalytic activityMP:0003031acidosisMP:0010128hypovolemiaVT:1000152wellness/fitness traitD009026mortalityPCO:0000008population growth rateGO:0006754ATP biosynthetic processGO:0017077oxidative phosphorylation uncoupler activityMP:0000066osteoporosisD061205vascular calcificationGO:0043687post-translational protein modification4abnormal1increased2decreased3occurrence7functional changeWarfarin2016-11-29T18:42:272016-11-29T18:42:27coumachlor2016-11-29T18:42:272016-11-29T18:42:27coumatetralyl2016-11-29T18:42:272016-11-29T18:42:27chlorophacinone2016-11-29T18:42:272016-11-29T18:42:27diphacinone2016-11-29T18:42:272016-11-29T18:42:27pindone2016-11-29T18:42:272016-11-29T18:42:273-[3-(4'-bromo[1,1'-biphenyl]-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2-benzopyrone2016-11-29T18:42:272016-11-29T18:42:27WCS_9606humans69158Rodentia spp.WCS_72873birdsWikiUser_17mammalsUnder carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis Under carboxylated clotting factors will not assemble on cell surfaces to form clot, FailurTissue2016-11-29T18:41:292016-12-03T16:37:53Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)OrganUBERON:0007798vascular system2016-11-29T18:41:292017-09-16T10:17:22Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboMolecular2016-11-29T18:41:292016-12-03T16:37:53Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removalBlood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tisCellular2016-11-29T18:41:292016-12-03T16:37:53Hemostasis, Depletion from blood of fully functional carboxylated clotting factorsHemostasis, Depletion from blood of fully functional carboxylated clotting factorsTissue2016-11-29T18:41:292016-12-03T16:37:53Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinoneIrreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle Molecular2016-11-29T18:41:292016-12-03T16:37:53Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunctionReduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunctionTissue2016-11-29T18:41:292016-12-03T16:37:53Impaired recruitment , Population trajectoryImpaired recruitment , Population trajectoryPopulation2016-11-29T18:41:292016-12-03T16:37:53Uncoupling of oxidative phosphorylation, Reduced ability to generate ATPUncoupling of oxidative phosphorylation, Reduced ability to generate ATPMolecularCL:0000255eukaryotic cell2016-11-29T18:41:292017-09-16T10:17:25Osteoporosis and vascular calcification, Bone deteriorationOsteoporosis and vascular calcification, Bone deteriorationIndividual2016-11-29T18:41:302016-12-03T16:37:53Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcinAnticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, ImpairmentMolecular2016-11-29T18:41:302016-12-03T16:37:53d6c88c99-1de4-4ee0-aa8d-880ce2f6309bb12eb29f-fb3a-408a-8c3f-55c252306aef2016-11-29T18:41:362016-12-03T16:38:04b12eb29f-fb3a-408a-8c3f-55c252306aefce751302-d18a-4d7d-9788-b4b9f2f65b4b2016-11-29T18:41:362016-12-03T16:38:04a2845b57-674b-4a2f-a1c5-05591071ebdcd6c88c99-1de4-4ee0-aa8d-880ce2f6309b2016-11-29T18:41:362016-12-03T16:38:04ce751302-d18a-4d7d-9788-b4b9f2f65b4ba732bf2f-a133-49d0-b1c4-f53f52523f452016-11-29T18:41:372016-12-03T16:38:04a732bf2f-a133-49d0-b1c4-f53f52523f452eabcc7d-7529-4d98-a820-a6a39a63aff62016-11-29T18:41:372016-12-03T16:38:042eabcc7d-7529-4d98-a820-a6a39a63aff62145a6e6-f0b9-4c41-85ec-260ad49c201c2016-11-29T18:41:372016-12-03T16:38:042145a6e6-f0b9-4c41-85ec-260ad49c201c2fb1dc2a-a83d-493d-8104-83fe9e6b875a2016-11-29T18:41:372016-12-03T16:38:04Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhageVKOR inhibition resulting in coagulopathyNot under active developmentUnder DevelopmentIncluded in OECD Work Plan1.31adjacentHighHighadjacentHighHighadjacentHighHighadjacentHighHighnon-adjacentHighHighnon-adjacentHighModeratenon-adjacentLowLowNot SpecifiedMaleNot SpecifiedFemaleHighAll life stagesHighHighModerateHigh<p><a href="#Life_Stage_Applicability">Life Stage Applicability</a>, <a href="#Taxonomic_Applicability"> Taxonomic Applicability</a>, <a href="#Sex_Applicability"> Sex Applicability</a><br />
<em>Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains. </em> Female rodents are less sensitive to ARs than males Female humans are more sensitive ti ARs than males</p>
Not SpecifiedNot SpecifiedNot SpecifiedNot SpecifiedNot SpecifiedNot SpecifiedNot Specified2016-11-29T18:41:172023-04-29T16:02:59